Dr Reddys Laboratories share climbs 2 per cent on new tablet launch
Dr Reddy’s Laboratories today announced the launch of Vigabatrin tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril® (Vigabatrin) tablets, USP, approved by United States Food & Drug Administration (USFDA).
According to the company, this product has been designated as a competitive generic therapy (CGT) by FDA. With the designation of CGT, the company has 180-day CGT exclusivity to market this product. The newly launched tablets will be available in the US market in the size of 500 mg tablets in a bottle count size of 100.
Sabril® brand and generic had revenues of around Rs 1,000 crore in Q3FY21 on a trailing twelve-month (TTM) basis. Dr Reddy’s Laboratories Ltd is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Their major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management & dermatology, with its major market including the USA, India, Commonwealth of independent states (CIS) countries, Europe and Russia.
The share price of the company reacted positively and was up by more than 2 per cent. On Tuesday, at the time of the closing bell, its shares were trading at Rs 4,492, up by 1.44 per cent. It registered an intraday high and an intraday low of Rs 4,528 and Rs 4,381, respectively.
---